• 1
    Hadziyannis SJ, Sevastianos V, Rapti IN, Tassopoulos N. Sustained biochemical and virological remission after discontinuation of 4 to 5 years of adefovir dipivoxil (ADV) treatment in HBeAg-negative chronic hepatitis B [Abstract]. HEPATOLOGY 2006; 44(Suppl): 23A.
  • 2
    Lok ASF, McMahon BJ. Chronic hepatitis B. AASLD Practice Guidelines. HEPATOLOGY 2007; 45: 507539.
  • 3
    Fattovich G, Giustina G, Sanchez-Tapias J, Quero C, Mas A, Olivotto PG, et al. Delayed clearance of HBsAg in compensated cirrhosis B: Relation to interferon alpha therapy and disease prognosis. Am J Gastroenterol 1998; 93: 896900.
    Direct Link:
  • 4
    Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126: 17501758.
  • 5
    Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991; 100: 182186.
  • 6
    Realdi G, Fattovich G, Hadziyannis S, Schalm S, Almasio P, Sanchez-Tapiaas J, et al. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: A multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol 1994; 21: 656666.
  • 7
    Chu CM, Liaw YF. HBsAg seroclearance in asymptomatic carriers of high endemic areas: Appreciably high rates during a long-term follow up. HEPATOLOGY 2007; 45: 11871192.
  • 8
    Perrillo R. Benefits and risks of interferon therapy for hepatitis B. HEPATOLOGY 2009;doi:10.1002/hep.22956.
  • 9
    Marcellin P, Lau GKK, Bonino F, Farci P, Hadziyannis S, Jin R, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 12061217.
  • 10
    Buster EHCJ, Flink HJ, Cakaglu Y, Simon K, Trojan J, Tabak F, et al. Sustained HBeAg and HBsAg loss after long term follow-up of HBeAg-positive patients treated with peginterferon α-2b. Gastroenterology 2008; 135: 459467.
  • 11
    Marcellin P, Piratvisuth T, Brunetto M, Bonino F, Lau GKK, Farci P, et al. Virological and biochemical response in patients with HBeAg-negative chronic hepatitis B treated with peginterferon alfa-2a (40-kD) with or without lamivudine: Results of 4 year-follow up [Abstract]. J Hepatol 2008; 48: S46.
  • 12
    Manensis EK, Hadziyannnis ES, Angelopoulou OP, Hadziyannis SJ. Prediction of treatment-related HBsAg loss in HBeAg-negative chronic hepatitis B: a clue from serum HBsAg levels. Antivir Ther 2007; 12: 7382.
  • 13
    Gish RG, Lau DT, Schmid P, Perrillo R. A pilot study of extended treatment duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B. Am J Gastroenterol 2007; 102: 27182723.
    Direct Link:
  • 14
    Moucari R, Mackiewicz V, Lada O, Ripault M-P, Castelnau C, Martinot-Peignoux M, et al. Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. HEPATOLOGY 2009;doi:10.1002/hep.22744.
  • 15
    Brunetto MR, Moriconi F, Bonino F, Lau GKK, Farci P, Yurdaydin C, Piratvisuth T, et al. Hepatitis B virus surface antigen levels—a guide to sustained response to pegylated interferon alfa-2a in HBeAg-negative chronic hepatitis B. HEPATOLOGY 2009;doi:10.1002/hep.22760.
  • 16
    Heathcote EJ, Gane EJ, deMan RA, Sing C, Sievert W, Mauss S, et al. Two year tenofovir disoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBeAg-positive patients with chronic hepatitis B (study 103), preliminary analysis [Abstract]. HEPATOLOGY 2008; 48(Suppl): 376A.
  • 17
    Bonino F, Marcellin P, Lau GKK, Hadziyannis S, Jin R, Piratvisuth T, et al. Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 2007; 56: 699705.
  • 18
    Erhardt A, Ludwig AD, Brunetto M, van Boemmel F, Wolf E, Goebel T, et al. HBV genotypes are the strongest predictors of response to interferon-alfa treatment: multivariate evaluation in 1229 hepatitis B patients [Abstract]. HEPATOLOGY 2008; 48(Suppl): 700A.